<DOC>
	<DOCNO>NCT01257893</DOCNO>
	<brief_summary>The purpose study compare rate aspirin resistance ( high residual platelet reactivity ) woman episodic chronic migraine woman without migraine . Emerging evidence suggest migraineurs , especially woman &lt; 45 year aura , increase risk stroke myocardial infarction ( MI , heart attack ) . The mechanism link migraine , stroke MI unclear although increased platelet activation aggregation observe migraine attack may plausible theory . Aspirin inexpensive , relatively safe antiplatelet drug reduces risk stroke MI . Preliminary data suggest aspirin 's ( 325mg ) therapeutic effect platelet inhibition may reduce migraineurs ( i.e. , aspirin resistance ) , thus limit aspirin 's effectiveness prevent stroke MI risk person migraine . Additional research warrant confirm finding migraineurs daily , low-dose aspirin 81 mg recommend first line therapy primary secondary prevention stroke MI The researcher hypothesize resistance aspirin 81mg may occur frequently woman episodic chronic migraine woman without migraine . The finding may important implication woman migraine use aspirin prevent migraine symptom comorbidities associate migraine include stroke MI .</brief_summary>
	<brief_title>Aspirin Resistance Women With Migraine</brief_title>
	<detailed_description>To test hypothesis rate aspirin resistance great woman episodic chronic migraine woman without migraine , three-group , randomize , double-blind , placebo-controlled , crossover design use test effect aspirin 81 mg platelet reactivity . Subjects randomized treatment order ( A ) aspirin 81 mg 10-14 consecutive day follow placebo 10-14 consecutive day ( B ) placebo 10-14 consecutive day follow aspirin 81 mg 10-14 consecutive day . Other treatment order , subject treat equally . Study procedure perform University Washington , duration study per subject approximately 28 day . Endpoints include : ) Aspirin Reaction Units ( ARU ) use point-of-care assay ( VerifyNow Aspirin™ ; Accumetrics , San Diego , CA ) ; b ) serum thromboxane B2 ; c ) percent platelet inhibition aspirin . Assessment adherence study regimen assess serum salicylate , medication diary , pill count . Data also collect migraine frequency , burden , disability , medication use treat headache . Subjects maintain migraine diary duration study ( 28 day ) . The target sample include woman episodic migraine ( n=40 ; n=20 MA , n=20 MO ) , woman chronic migraine ( n=40 ) non-migraine control ( n=40 ) . The specific aim study follow : - Compare rate aspirin resistance woman without migraine follow 10-14 consecutive day aspirin 81 mg treatment - Compare rate aspirin resistance woman episodic migraine chronic migraine follow 10-14 consecutive day aspirin 81 mg treatment - Compare rate aspirin resistance woman migraine aura ( MA ) migraine without aura ( MO ) follow 10-14 consecutive day aspirin 81 mg placebo treatment - Compare rate aspirin resistance woman migraine high monthly migraine frequency low monthly migraine frequency follow 10-14 consecutive day aspirin 81 mg treatment</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Women 1850 year age , childbearing potential Able read , speak , understand English except patient blind , case ability understand English require . Episodic Migraine Group : Documented diagnosis episodic migraine 2year period precede enrollment , use International Headache Society ( IHS ) criterion . Frequency 214 migraine day three month prior enrollment . Equal number ( n=20 ) document diagnosis migraine aura ( MA ) migraine without aura ( MO ) . For woman diagnosis MA , focal neurologic symptom must precede accompany headache ( aura ) least one headache 12 month prior enrollment . Chronic Migraine Group : Frequency ≥ 15 headache day per month ≥ 3 month . On least 8 day per month ≥ 3 month headache fulfil criterion pain associate symptom MO . Control group : No diagnosis migraine , confirm Migraine Assessment Tool . Pregnancy lactation Postmenopausal , either natural surgical ( bilateral oophorectomy ) Current prescribe daily medication regimen include follow : warfarin , glycoprotein IIb/IIIa inhibitor ( abciximab , tirofiban ) , antiplatelet agent ( clopidogrel , ticlopidine , dipyridamole ) , nonsteroidal antiinflammatory drug ( e.g. , ibuprofen , naproxen , celecoxib ) , Vitamin E dose &gt; 800 IU per day , Omega3 fatty acid dose &gt; 3 g/day , willow bark ( amount ) , aspirin aspirincontaining medication . Aspirin intolerance allergy , peptic ulcer disease . Platelet count &lt; 150,000/µl &gt; 450,000/µl . Hemoglobin &lt; 10 g/dL . History current diagnosis myocardial infarction , stroke , coronary artery disease , peripheral arterial disease , diabetes mellitus , renal disease . Unable tolerate washout protocolrestricted medication and/or supplement ( see # 3 ) . Family ( firstdegree relative ) patient history bleed hemorrhagic disorder include von Willebrand Factor Deficiency , Glanzmann Thrombasthenia , BernardSoulier Syndrome myeloproliferative syndrome . Major surgical procedure , trauma , blood donation , major blood loss ( &gt; 300 cc ) within 30 day prior enrollment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>migraine</keyword>
	<keyword>chronic migraine</keyword>
	<keyword>migraine aura</keyword>
	<keyword>migraine without aura</keyword>
	<keyword>aspirin</keyword>
	<keyword>platelet</keyword>
</DOC>